

![]() |
|||||||||||||
|
| All | Since 2021 | |
| Citation | 7304 | 4079 |
| h-index | 28 | 23 |
| i10-index | 181 | 77 |
Submit Article
Search
News & Updation
ECONOMIC VIABILITY OF 6-MONTH BPAL/BPALM REGIMENS VERSUS LEGACY MDR-TB THERAPIES: A SYSTEMATIC REVIEW
Amit Bhattacharjee*, Nikki Tripathi, Shourabh, Kanika, Govind Mohan, Snehpreet Kaur Saini, Tushar Soni
ABSTRACT This systematic review synthesizes and quantifies evidence regarding the economic viability, cost-effectiveness, and budget impact of 6-month BPaL/BPaLM regimens compared with legacy longer (18–24 months) and shorter (9–11 months) MDR-TB therapies across varied income settings. Multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) presents a severe global health threat, historically managed with 9-to-24-month regimens plagued by poor adherence, severe drug toxicity, and substantial economic toxicity. The introduction of 6-month, all-oral bedaquiline, Pretomanid and linezolid with or without moxifloxacin (BPaL/BPaLM) regimens has redefined clinical management. However, national tuberculosis programs (NTPs) require systematic health economic evaluations to justify programmatic transition. Following PRISMA 2020 and CHEERS 2022 guidelines, peer-reviewed economic evaluation literature was evaluated. BPaL/BPaLM regimens consistently demonstrate economic dominance or high cost-effectiveness across high-burden environments (e.g., South Africa, India, Georgia, Philippines, Moldova, Indonesia, Kyrgyzstan, Nigeria). Direct treatment cost reductions ranged from 20% to 78%, driven by a 60–80% decrease in health service utilization, outpatient monitoring visits, and inpatient bed-days. Budget impact models project overall 5-year programmatic expenditure reductions of 9–32% once scaled, alongside marked decreases in catastrophic household costs. Keywords: Multidrug resistant tuberculosis, Economic Evaluation, Cost-Effectiveness, Budget Impact Analysis, Regimen. [Download Article] [Download Certifiate] |
